Are Psilocybe cubensis Strain Names Scientifically Meaningful

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Psilocybe cubensis strain names are not formally standardized taxonomic names. Labels such as Golden Teacher, B+ and Penis Envy can identify cultivated lines or selections, but the name alone does not prove a fixed genotype, documented pedigree, stable phenotype or predictable potency. Genome research shows that many cultivated P. cubensis lines are closely related, while material sold or maintained under similar names can still show genetic differences. Chemical studies also show substantial variation between strains and between individual mushrooms carrying the same strain label.

Where Psilocybe cubensis strain names come from

When you see a name such as Golden Teacher, B+, Penis Envy, Cambodian or Amazonian, you are usually seeing a cultivated lineage label. These names developed through cultivation, selection, informal breeding and repeated exchange of spores or living cultures.

They do not occupy the same taxonomic level as Psilocybe cubensis. The National Center for Biotechnology Information records Psilocybe cubensis as a species. A label such as Golden Teacher sits below that species designation in informal cultivation terminology.

Scientific literature now uses many of these familiar names because researchers need a practical way to identify the material being tested. A 2024 chemical study, for example, analyzed P. cubensis samples labeled Blue Meanie, Creeper, B+, Texas Yellow and Thai Cubensis. Those labels identified the sampled cultivated material, while the formal species remained P. cubensis.

A 2025 review of P. cubensis research noted that dozens of strain names are recognized through cultivation communities while formal scientific documentation remains limited. The same review described strain diversity as a mixture of inherited genetic variation, selection and environmental effects.

This gives you an important distinction. A strain name can carry useful provenance when the lineage has been carefully recorded. The scientific value of that name depends on the records and biological material attached to it.

Why cubensis strain names are not taxonomic names

Taxonomy gives you formally recognized ranks such as genus and species. Psilocybe is the genus and cubensis is the species epithet. Names such as Golden Teacher and B+ do not represent formally described species.

The word strain is used more loosely.

In microbiology and mycology, a strain can refer to a particular genetic line, isolate or laboratory culture within a species. In P. cubensis discussions, strain can also refer to a named cultivated population that has passed through multiple generations, selections or sources.

Those usages are not always equivalent.

If you are evaluating a scientific paper, you should ask what biological material actually sits behind the strain label. Useful records can include provenance, culture history, genome data, phenotype, voucher material and chemical analysis.

Several related terms help clarify what a name may represent.

TermWhat it tells you
SpeciesThe formal taxonomic unit, such as Psilocybe cubensis
StrainA genetic or cultivated line within the species, though usage varies
IsolateMaterial derived from a particular biological collection or culture
CultivarA cultivated selection maintained for particular inherited traits
LandraceA locally associated population shaped through longer-term selection and adaptation
GenotypeThe genetic composition of the material
PhenotypeObservable traits produced through genetics and environmental conditions

You should use the term landrace especially carefully. A geographic strain name does not by itself demonstrate that the material represents a long-established local population. Provenance records and genetic sampling would be needed to support that claim.

The same principle applies to cultivar. A named line may function as a cultivar in practical cultivation language, but the name by itself does not tell you how stable or genetically defined the line is.

What genetics research shows about cubensis strain stability

Genomic research has started to test assumptions that previously rested mainly on strain names.

A 2023 Current Biology study sequenced 38 Australian P. cubensis isolates and compared them with 86 genomes from cultivated lines. Researchers found that cultivated material generally showed lower genetic diversity, lower heterozygosity, higher linkage disequilibrium and signs of repeated selfing or clonal propagation. Most cultivated lines also traced back to genetically related founding populations.

This tells you that many named cultivated lines share substantial ancestry.

The same research also found that similarly named material from different sources did not always show close genetic similarity. That result places a clear limit on what a strain label can establish by itself.

A strain name can therefore act as a lineage reference while still containing genetic uncertainty.

Genotype and phenotype are separate measurements

Your genotype is the inherited genetic material present in a specimen or culture. Phenotype describes observable features produced through the interaction of genetics and environmental conditions.

For P. cubensis, phenotype can include features such as fruiting-body form, pigmentation, cap shape, growth characteristics and other visible traits.

Two cultures can look similar while carrying genetic differences. Genetically related cultures can also show visible differences when developmental or environmental conditions differ.

That relationship becomes especially relevant when you compare strain names. A recognizable phenotype can help track a cultivated line, but appearance alone cannot establish an exact genotype.

Genomic sequencing gives researchers a much stronger basis for determining relatedness.

Cultivated cubensis lines share extensive ancestry

The 2023 population-genomics study found low allelic diversity across many cultivated samples. Researchers also found low diversity across coding regions of the psilocybin biosynthetic gene cluster in most cultivated lines.

This does not mean every cultivated P. cubensis sample is genetically identical. The study found distinct genetic groupings and differences between cultivated material and the more genetically diverse Australian population.

For you, the main implication is that dozens of different names do not automatically represent dozens of deeply separated genetic populations.

A name can reflect a selection history, recognizable phenotype, mutation, hybrid line or source history while remaining closely related to other named cubensis material.

Monokaryons, dikaryons and why strain genetics can change

Part of the naming problem becomes clearer when you look at the fungal life cycle.

P. cubensis is a basidiomycete fungus. Genetic studies support a tetrapolar mating-compatibility system in this species. In this type of system, mating compatibility depends on genetic differences at two mating loci.

A germinated haploid spore can produce monokaryotic mycelium. Compatible monokaryons can combine to form dikaryotic mycelium containing genetically distinct nuclei. Recombination associated with sexual reproduction can then generate new combinations of alleles in later spores.

This has direct consequences for strain identity.

If you maintain one living dikaryotic culture through clonal propagation, its genetic identity can remain much more constrained than material repeatedly regenerated through spores.

When you start again from spores, you are sampling recombinant offspring. Those offspring can contain different genetic combinations even though the strain name remains the same.

The label may therefore persist through generations while the exact genotype changes.

This is one reason a strain name cannot serve as a substitute for a documented isolate identifier in controlled research.

Is Golden Teacher genetically stable

You should not assume that every sample called Golden Teacher represents one genetically identical or universally stable line.

Golden Teacher is one of the best-known names attached to cultivated P. cubensis, and the name appears in modern genomic and chemical research. That scientific use confirms that researchers can study specific Golden Teacher-labeled samples. It does not establish one genetic profile shared by every sample carrying the name.

The 2023 population-genomics study included a substantial group of Golden Teacher-labeled genomes as part of its cultivated dataset. The researchers detected genetic clustering across cultivated populations while also reporting that similarly named cultivars from different sources were not always genetically similar.

That is the key distinction if you are asking whether Golden Teacher is genetically stable.

A particular Golden Teacher isolate can be maintained as a defined culture. A collection of unrelated materials carrying the Golden Teacher name cannot automatically be treated as one genotype.

Recent chemical research also includes Golden Teacher-related material. A 2026 study examined a Jack Frost × Golden Teacher line alongside 13 other P. cubensis strains under controlled conditions. Even with cultivation, drying, extraction and analysis standardized, researchers found substantial chemical differences across strains and measurable variation among individual fruiting bodies from the same strain.

The strain name therefore tells you less than a documented genotype plus chemical profile.

What B+ and Penis Envy names tell you

B+ and Penis Envy show the same naming issue from different angles.

B+ appears in peer-reviewed chemical research. A 2024 study measured three intact mushrooms from each of five named P. cubensis strains. B+ averaged 1.134 percent combined psilocybin and psilocin by dry weight in the sampled material. Other named strains in the same experiment ranged from 0.879 percent to 1.36 percent.

That number describes the tested B+ material. It should not be applied automatically to every mushroom called B+.

Penis Envy has also appeared in genomic and chemical research. In the 2026 controlled study of 14 P. cubensis strains, Penis Envy produced the highest measured psilocin concentration among the tested lines at 1.77 milligrams per gram, while another strain had the highest total measured tryptamine concentration.

This distinction is useful because it shows why a single reputation for potency can oversimplify the chemistry. Different alkaloids vary independently and total concentrations can change from one sample to another.

Why the same named strain can test differently

When two samples carry the same strain name and produce different results, several biological explanations are possible.

One source of variation is genetic.

A named strain may have passed through repeated spore generations. Recombination can produce genetically different descendants while the original label remains attached to them.

Another source is selection. A particular phenotype may be selected and maintained from a broader population. Different researchers or cultivators can select different descendants from material that started under the same name.

Environmental conditions can also influence phenotype and chemistry.

Even carefully controlled laboratory studies find variation among individual fruiting bodies.

The 2026 study of 14 P. cubensis strains controlled cultivation, drying, extraction and analytical procedures. Total tryptamine concentrations still ranged from 2.62 to 20.65 milligrams per gram across strains, a difference of more than 7.8-fold.

Researchers also separately analyzed five fruiting bodies within selected strains. The coefficients of variation for psilocybin concentration ranged from roughly 13 percent to 23 percent in the reported groups. A Jack Frost × Golden Teacher line had individual measurements ranging from 6.81 to 12.38 milligrams per gram of psilocybin.

This means that chemical variability exists at several levels.

  • Between named strains
  • Between genetic lines carrying related names
  • Between individual fruiting bodies from one strain
  • Across developmental stages
  • Across cultivation conditions
  • Across storage conditions
  • Across analytical methods

If you need a chemical specification, direct analytical measurement gives you stronger evidence than the strain label.

Does a Psilocybe cubensis strain name predict potency

A strain name can be associated with measured chemical tendencies in a defined research collection, but the name alone cannot reliably predict the potency of an untested sample.

The available studies make this clear.

In the 2024 analysis of five strains, Creeper averaged 1.36 percent combined psilocybin and psilocin, Blue Meanie averaged 1.221 percent, B+ averaged 1.134 percent, Texas Yellow averaged 1.103 percent and Thai Cubensis averaged 0.879 percent. Individual mushrooms within the same named groups also differed.

The 2026 study found an even wider range when six tryptamines were measured across 14 strains. Total concentrations differed by more than sevenfold. It also found no consistent relationship showing that a high concentration of one tryptamine predicted high concentrations of the others.

Older research had already documented large chemical variability in P. cubensis. Controlled cultures showed psilocybin concentrations changing substantially across samples and material from different collections varied even more.

If you are reading a statement such as “this strain always contains more psilocybin,” you should look for direct chemical testing of the exact biological material being discussed.

Why strain identity affects research supply and dose consistency

Strain naming becomes scientifically important when mushroom material is being studied as a research input.

A study needs reproducibility. If one research group uses a named strain and another group later uses different genetic material under the same name, direct comparison becomes harder.

Chemical variation creates a second problem.

Whole-mushroom material contains concentrations of psilocybin, psilocin and minor tryptamines that can vary between samples. The 2026 controlled study specifically noted that this variation could produce inconsistent pharmacological exposure when dose calculations rely on mushroom biomass alone.

For research involving psychedelics, stronger biological authentication and chemical characterization can make findings easier to reproduce and interpret. That is especially relevant as scientific interest in psilocybin expands into pharmacology and therapeutic research.

A strain label can remain useful as one part of the record. Research-grade documentation can add an isolate identifier, genetic profile, culture history, phenotype records and analytical chemistry.

How standardisation is approached in a research setting

If you want a named P. cubensis line to function as reproducible research material, the name should sit within a larger identity record.

Document the source material

You can begin with a specific isolate or culture and assign it a persistent identifier. This creates a reference point that remains separate from the public strain name.

The record can include collection history, source date, parent material and any known breeding history.

Record genotype

Genome sequencing or other validated genetic markers can establish the identity and relatedness of your material.

The 2023 population-genomics study used genome-wide single nucleotide polymorphisms and single-copy genes to compare cultivated and naturalized P. cubensis populations. This type of analysis can distinguish genetic relationships that visual inspection cannot resolve.

Record phenotype

Phenotypic data can document visible and developmental traits associated with a specific line.

This can include fruiting morphology, pigmentation and other reproducible biological characteristics.

Phenotype is most useful when you keep it tied to a known genotype and defined research conditions.

Use controlled propagation

The distinction between monokaryotic and dikaryotic material becomes relevant here.

A clonally maintained dikaryotic culture can preserve a defined biological line more consistently than repeatedly restarting material from sexually produced spores. Spore-derived offspring involve recombination and can produce new genotypes.

Your propagation history should therefore form part of the research record.

Measure chemistry directly

Analytical chemistry can establish the concentrations of psilocybin, psilocin and other target compounds in the material actually used.

Liquid chromatography coupled with tandem mass spectrometry has been used to quantify psilocybin and psilocin in named P. cubensis strains with validated analytical performance.

When chemical exposure affects the research question, measured concentration gives you direct data that a strain name cannot provide.

Conclusion

You can treat a P. cubensis strain name as a useful label when you know what evidence accompanies it.

By itself, the name can tell you that the biological material has been represented as a particular cultivated line. With documented provenance, it can also help trace related cultures and selections.

The label becomes scientifically stronger when several records agree.

  • The species identity has been confirmed
  • The isolate has a unique identifier
  • The lineage history is documented
  • Genetic information is available
  • Phenotypic characteristics are recorded
  • Chemical composition has been tested
  • Propagation history is retained

Without those records, Golden Teacher, B+, Penis Envy and similar names should be treated as informal lineage labels rather than fixed biological specifications.

As you assess how strain identity can be documented for reproducible research, we at Rose Hill Life Sciences work as a psychedelic research organization focused on the production and research of Psilocybe cubensis at the intersection of science and therapeutic integration, including our Massachusetts research work where strain identity, chemical characterization and research consistency are relevant to the scientific use of fungal material.

For scientific purposes, the strongest record follows the actual biological material. A strain name can provide useful lineage context. Genotype, documented provenance, propagation history and analytical testing provide the evidence needed to determine what that named material represents.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Bryan Smith

Research & Development

Bryan Smith is an accomplished biotech leader in small molecule drug discovery and development. With over 18 years of experience at Deciphera Pharmaceuticals, he last served as Vice President of Biological Sciences and Research Site Head, until their acquisition by Ono Pharmaceutical in 2024. His work directly contributed to the discovery and development of FDA-approved therapies Qinlock™ (ripretinib) and Romvimza™ (vimseltinib), along with multiple additional compounds advancing through clinical trials.

In 2024, Bryan transitioned to independent consulting and scientific advisory roles. Through Smith Biotech Consulting LLC, he provides expert guidance on all phases of drug discovery, preclinical/clinical planning, IND/NDA support, due diligence, and pipeline strategy. Bryan holds a PhD in Biochemistry from the University of Wisconsin-Madison.  

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Chief Executive Officer

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over 25 years experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including 10+ years at Deciphera Pharmaceuticals, where she served as SVP, Chief Development Officer, and played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in corporate strategy, regulatory affairs, portfolio management, quality assurance, and clinical operations, alongside a proven track record of fostering inclusivity and mentorship within her teams.

In addition to her role as Chief Executive Officer at Rose Hill, she is the founder of JP BioPharma Consulting where she advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Her most recent drug approvals include QINLOCK® for gastrointestinal stromal tumors and ROMVIMZA® for tenosynovial giant cell tumors. Throughout her career Jama has contributed to the development of 9 approved therapies and advanced development of numerous novel clinical assets.

Education: B.Sc. in Microbiology, University of New Hampshire.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Mycologist

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.